Daratumumab is a human monoclonal antibody that targets CD38 a cell surface protein that is overexpressed on multiple myeloma MM) cells.

[accordions]
[accordion title= “Chemical Properties“]

[/accordion]

[accordions]
[accordion title= “References and Literature“]

1. Michel de Weers, et al. Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors. J Immunol. 2011 Feb 1;186(3):1840-8.

[/accordion]